In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
|Articles|May 5, 2021
Biden Administration Announces Support for Lifting Patent Protections on COVID-19 Vaccines
Author(s)Killian Meara
As countries like India and those in South America continue to struggle, the loosening of protections will help in their fight against the virus.
Advertisement
On Wednesday, the Biden administration announced that they will support the waiving of all intellectual property protections on COVID-19 vaccines, in an effort to aid countries around the world who are dealing with severe surges in cases of the disease.
The loosening of the protections will help to increase the global supply of doses.
The World Trade Organization has had a proposal to suspend the intellectual property protections in an effort to ramp up vaccine production, but the United States has been a leading opposer since it was introduced.
However, many congressional democrats have been increasing pressure on Biden to support the proposal.
Major Pharmaceutical and biotech companies have also been against it, but have now stated that they will help by increasing the supply of their vaccines.
The United States trade representative, Katherine Tai, made a statement Wednesday afternoon announcing the administration’s new position.
“This is a global health crisis, and the extraordinary circumstances of the Covid-19 pandemic call for extraordinary measures,” Tai said. “The administration believes strongly in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protections for Covid-19 vaccines.”
In the coming weeks, India and South Africa, who originated the proposal, are expected to continue discussions as they prepare a revised plan for nations around the globe to consider.
Advertisement
Related to this article
Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.
CDC is continuing its investigation into 4 multistate Salmonella and E coli outbreaks, led by a 76-case alfalfa sprout cluster across 16 states and a recalled raw milk cheese.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Demonstrating a diagnostic test works is no longer enough. Clinicians and laboratories also need evidence on how to adopt it in everyday practice. Andrea Prinzi, PhD, MPH, SM(ASCP), explains how implementation science can help infectious disease and clinical microbiology teams turn evidence into routine care.
Kenya reported its first imported Bundibugyo Ebola death as the Democratic Republic of Congo (DRC) outbreak surpassed 8,600 confirmed cases and 4,148 deaths, with 896 patients hospitalized in isolation. Here is a report on the latest numbers as well as vaccine and therapeutic study updates.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Advertisement
Advertisement